TABLE 3.
MIC and MFC ranges for C. nivariensis and C. glabrata
| Organism | Amphotericin B
|
Itraconazole
|
Voriconazole
|
Fluconazole
|
Posaconazole
|
Flucytosine
|
Caspofungin
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC50 (μg/ml) | MIC90 (μg/ml) | MFC50 (μg/ml) | MFC90 (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) | MFC50 (μg/ml) | MFC90 (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) | MFC50 (μg/ml) | MFC90 (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) | MFC50 (μg/ml) | MFC90 (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) | MFC50 (μg/ml) | MFC90 (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) | MFC50 (μg/ml) | MFC90 (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) | MFC50 (μg/ml) | MFC90 (μg/ml) | |
| C. nivariensis (n = 13) | 0.5 | 0.5 | 0.5 | 2 | 8a | >16 | >16 | >16 | 0.5 | 4 | >16 | >16 | 64 | >64 | >64 | >64 | 1 | 2 | >16 | >16 | 0.25 | 0.5 | 2 | 32 | 0.5 | 1 | 2 | 2 |
| C. glabrata (n = 13) | 0.5 | 1 | 0.5 | 2 | 1 | 1 | >16 | >16 | 0.5 | 0.5 | >16 | >16 | 8 | 32 | >64 | >64 | 0.5 | 4 | >16 | >16 | <0.125 | <0.125 | <0.125 | <0.125 | 1 | 2 | 2 | >64 |
| C. glabrata (azole- resistant strainsb) | 0.5 | 1 | NAc | NA | >16 | >16 | NA | NA | 2 | 8 | NA | NA | 64 | >64 | NA | NA | 4 | >16 | NA | NA | <0.125 | <0.125 | NA | NA | 1 | 1 | NA | NA |
a
Values in boldface indicate significant differences in MIC or MFC values between C. nivariensis and C. glabrata.
b
Data were compiled from unpublished results of routine MIC testing by the MRL of nine clinical isolates of C. glabrata that exhibited the most significant resistance to azole antifungal agents.
c
NA, MFC data are not available for these isolates.